Fauchais A L, Michon-Pasturel M, Rugale C, Asseray N, Bulckaen H, Queyrel V, Puisieux F, Hebbar M, Hachulla E, Hatron P Y, Devulder B
Service de médecine interne, hôpital Claude-Huriez, CHRU, place de Verdun, 59037 Lille, France.
Rev Med Interne. 2001 Feb;22(2):127-31. doi: 10.1016/s0248-8663(00)00302-7.
To determine aged-related variations in clinical and biological presentation and outcome in Wegener's granulomatosis.
In a retrospective cohort study of 35 patients with a diagnosis of Wegener's granulomatosis, 24 patients (69%) younger than 60 years of age and 11 (31%) aged 60 years or older were compared for clinical and biological characteristics.
Clinical presentation was the same in the two groups; lymphopenia was more common in the elderly group (P > 0.05). Despite a similar treatment regime, outcome was significantly worse for the elderly group (> or = 60 years), with a mortality rate of 36% versus 8% in the control group. Mortality was essentially due to delayed infectious complications, raising the problem of a less intensive immunosuppressive treatment after remission.
确定韦格纳肉芽肿病在临床、生物学表现及预后方面与年龄相关的差异。
在一项对35例诊断为韦格纳肉芽肿病患者的回顾性队列研究中，比较了24例年龄小于60岁的患者（69%）和11例年龄60岁及以上的患者（31%）的临床和生物学特征。
两组的临床表现相同；淋巴细胞减少在老年组更常见（P>0.05）。尽管治疗方案相似，但老年组（≥60岁）的预后明显更差，死亡率为36%，而对照组为8%。死亡主要归因于感染并发症延迟出现，这引发了缓解后免疫抑制治疗强度较低的问题。
